Also trades as: 0RC7.L (LSE) · $vol 0M
HNSA.ST STO
Hansa Biopharma AB (publ)
1W: +2.5%
1M: -25.4%
3M: -4.0%
YTD: -10.3%
1Y: +5.9%
3Y: -26.6%
5Y: -73.0%
kr 33.18 ($3.30)
-0.94 (-2.75%)
Weekly Expected Move ±6.2%
kr 29
kr 31
kr 33
kr 35
kr 37
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$222M
+29.7% ▲
5Y CAGR: +105.3%
Gross Profit
$139M
+58.0% ▲
5Y CAGR: +93.6%
Operating Income
-$521M
+18.4% ▲
Net Income
-$529M
+34.4% ▲
EPS (Diluted)
$-6.52
+49.2% ▲
EBITDA
-$409M
+36.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $34M | $155M | $134M | $171M | $222M |
| YoY Growth | +455.6% | +356.1% | -13.2% | +27.8% | +29.7% |
| Cost of Revenue | $15M | $38M | $63M | $84M | $84M |
| Gross Profit | $18M | $116M | $71M | $88M | $139M |
| Gross Margin | 54.5% | 75.1% | 52.9% | 51.2% | 62.4% |
| R&D Expenses | $231M | $346M | $411M | $376M | $305M |
| SG&A Expenses | $327M | $338M | $450M | $344M | $357M |
| Operating Expenses | $558M | $692M | $859M | $726M | $659M |
| Operating Income | -$540M | -$576M | -$788M | -$638M | -$521M |
| Operating Margin | -1592.7% | -372.8% | -588.0% | -372.3% | -234.3% |
| Interest Expense | $694K | $44M | $106M | $134M | $118M |
| Income Before Tax | -$548M | -$610M | -$831M | -$804M | -$527M |
| Tax Expense | $152K | $1M | $908K | $3M | $2M |
| Net Income | -$548M | -$611M | -$832M | -$807M | -$529M |
| Net Margin | -1618.4% | -395.5% | -620.3% | -471.2% | -238.1% |
| EPS (Diluted) | $-12.33 | $-13.60 | $-15.83 | $-12.84 | $-6.52 |
| EBITDA | -$539M | -$554M | -$715M | -$642M | -$409M |
| Shares Outstanding | 44M | 45M | 53M | 63M | 81M |